Fungal infections are a major contributor to infectious disease-related deaths across the
globe. Candida species are among the most common causes of invasive mycotic disease …

Systemic fungal infections pose a serious clinical problem. Treatment options are limited,
and antifungal drug resistance is increasing. In addition, a substantial proportion of patients …

Background. Candida auris, a multidrug-resistant yeast that causes invasive infections, was
first described in 2009 in Japan and has since been reported from several countries …

Background Candida auris has emerged globally as an MDR nosocomial pathogen in ICU
patients. Objectives We studied the antifungal susceptibility of C. auris isolates (n= 350) from …

Candida auris is an emerging multidrug-resistant yeast that causes serious invasive
infections with high mortality. It was first discovered in 2009, and since then, individual cases …

Candida albicans and the emerging non-albicans Candida spp. have significant clinical
relevance among many patient populations. Current treatment guidelines include …

Within the limited antifungal armamentarium, the azole antifungals are the most frequent
class used to treat Candida infections. Azole antifungals such as fluconazole are often …

Despite abundant research in the field of antifungal drug discovery, fungal infections remain
a significant healthcare burden. There is an emerging need for the development of novel …

The Candida genus comprises opportunistic fungi that can become pathogenic when the
immune system of the host fails. Candida albicans is the most important and prevalent …

Fungal infections, such as candidiasis caused by Candida, pose a problem of growing
medical concern. In developed countries, the incidence of Candida infections is increasing …